RecruitingPhase 1NCT06943677

A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsules in Subjects With Advanced Malignant Tumors

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment

80 participants

Start Date

May 26, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Malignant Cancer

Summary

The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3019 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3019 capsules.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TQB3019 capsules for people with advanced malignant cancer. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTQB3019 capsules

TQB3019 capsule is a targeted protein degrader

Locations(15)

Cancer Institute & Hospital.Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

Zhengzhou, Henan, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Heze Municipal Hospital

Heze, Shandong, China

The Cancer Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, China

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Tongji Hospital of Tongji University

Shanghai, Shanghai Municipality, China

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China

Mianyang Central Hospital

Mianyang, Sichuan, China

Affiliated Hospital of North sichuan Medical college

Nanchong, Sichuan, China

TianJin Medical University Cancer Institute&Hospital

Tianjin, Tianjin Municipality, China

Institute of Hematology ＆Blood Diseases Hospital,Chinese Academy of Medical Sciences ＆Peking Union Medical College

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06943677

Related Trials

Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors

NCT074825921 location